Information Technology

NexgenRx Reports Higher Third-Quarter Revenue, Pre-Tax Income and EBITDA

NexgenRx reported higher revenue, pre-tax income and EBITDA for the third quarter ended September 30, 2026, although income tax expense resulted in a net loss for the period.

Published:
Reading Time
3 min

NexgenRx Inc. reported higher revenue, income before taxes and EBITDA for the third quarter ended September 30, 2026. Revenue reached $4,904,857, income before taxes was $843,735 and EBITDA was $1,048,210, representing increases of 8%, 48.8% and 18.1%, respectively, compared with the same period in 2025.

#Third-quarter financial performance

The company said quarterly revenue rose 8.0% from the comparable period in 2025, primarily because of higher transaction fee revenue linked to increased transaction volumes and business growth. Gross profit reached $4.2 million.

Income before income taxes increased from $566,925 in the prior-year period to $843,735. NexgenRx attributed the improvement to business expansion, cost management and operational improvements.

EBITDA rose from $887,671 in the prior-year period to $1,048,210. The company said the change reflected its ability to support higher business volumes without a proportionate increase in operating expenses.

#Tax expense leads to quarterly net loss

Despite the increase in pre-tax earnings, NexgenRx recorded a net loss of $63,993 for the quarter, compared with net income of $589,780 in the same period last year.

The company said the result was caused by income tax expense of $907,728, recognised as NexgenRx continued to generate taxable profits and had fully used its remaining tax loss carry-forwards. The tax expense included $716,912 in non-cash deferred income tax expense related to the recognition and use of deferred tax assets, along with $190,816 in current income tax expense.

#Nine-month results

For the nine months ended September 30, 2026, revenue increased 13.4% from the corresponding period in 2025 to $15.1 million. Net income rose 46.7% to $2.2 million, while EBITDA increased 57.9% to $3.70 million.

NexgenRx said the nine-month performance reflected the combined effects of business expansion, disciplined cost management and ongoing operational improvements.

#Financial position and operating initiatives

At September 30, 2026, shareholders’ equity stood at $8.9 million. Cash and cash equivalents totalled $4.1 million, while restricted client funds held on deposit amounted to $29.6 million.

The company said its financial resources and capital management support day-to-day operations, strategic investments, future business opportunities and its ongoing dividend program.

NexgenRx identified technology modernisation, digital transformation and process automation as continuing priorities. Its Artificial Intelligence Committee has incorporated several AI-based initiatives into operations, with applications focused on workflow efficiency, analytical capabilities and decision-making.

#Business profile and forward-looking caution

NexgenRx describes itself as an independent full-service third-party administrator and technology solutions provider in Canada. Its services include eligibility, enrolment, hour bank and mobile access capabilities, claims adjudication and provider network coverage, delivered to Plan Sponsors through a SaaS model.

The company said its forward-looking information is subject to risks including uncertainty over whether its strategies and business plans will produce the expected benefits, the availability and cost of capital, technology development, expenditure requirements, changes in technology, laws and regulations, and cybersecurity risks. NexgenRx cautioned that actual events or results may differ materially from those anticipated.

#Key Takeaways

  • Third-quarter revenue was $4,904,857, up 8% from the same period in 2025.
  • Income before taxes increased 48.8% to $843,735, while EBITDA rose 18.1% to $1,048,210.
  • The company reported a net loss of $63,993 after recognising $907,728 in income tax expense.
  • For the nine months ended September 30, 2026, revenue was $15.1 million and EBITDA was $3.70 million.
  • At September 30, 2026, NexgenRx reported $8.9 million in shareholders’ equity, $4.1 million in cash and cash equivalents, and $29.6 million in restricted client funds.

Original source: Read original article

Frequently Asked Questions